Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
COGT Stock Chart & Stats
$37.95
-$0.07(-0.91%)
At close: 4:00 PM EST
$37.95
-$0.07(-0.91%)
Day’s Range― - ―
52-Week Range$3.72 - $43.73
Previous CloseN/A
Volume181.15K
Average Volume (3M)2.10M
Market Cap
$5.66B
Enterprise Value$5.52B
Total Cash (Recent Filing)$390.89M
Total Debt (Recent Filing)$60.56M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Mar 17, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding152,053,960
10 Day Avg. Volume1,481,269
30 Day Avg. Volume2,101,465
Financial Highlights & Ratios
PEG Ratio-1.92
Price to Book (P/B)3.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.89
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.77K
Enterprise Value/Ebitda-18.57
Forecast
1Y Price Target
$52.00Price Target Upside37.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPEAK trial data indicate the bezuclastinib plus sunitinib combination produced substantially longer progression-free survival and a notably higher response rate versus sunitinib alone, supporting potential adoption in second-line GIST.
Pipeline DiversificationPlanned INDs and early-stage programs targeting KRAS and JAK2, along with upcoming FGFR clinical data, diversify the pipeline and expand potential commercial opportunities beyond current indications.
Regulatory ProgressFDA Breakthrough Therapy designation for the bezuclastinib and sunitinib combination and planned NDA filings for mastocytosis create clearer regulatory pathways that could accelerate approval chances.
Bears Say
Capital Structure And DilutionRecent equity and convertible note offerings increase share count and could dilute existing shareholders, putting pressure on near-term stock performance.
Competitive PositioningLimited differentiation versus the established competitor and a lower response rate create a need for substantial commercial investment to gain market share against the entrenched franchise.
Safety And MonitoringHigher-rate thrombocytopenia and some liver enzyme elevations raise safety and monitoring concerns that could limit patient uptake and prompt stricter label requirements.
Cogent Biosciences News
COGT FAQ
What was Cogent Biosciences’s price range in the past 12 months?
Cogent Biosciences lowest stock price was $3.72 and its highest was $43.73 in the past 12 months.
What is Cogent Biosciences’s market cap?
Cogent Biosciences’s market cap is $5.66B.
When is Cogent Biosciences’s upcoming earnings report date?
Cogent Biosciences’s upcoming earnings report date is Mar 17, 2026 which is in 31 days.
How were Cogent Biosciences’s earnings last quarter?
Cogent Biosciences released its earnings results on Nov 03, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.516 by $0.016.
Is Cogent Biosciences overvalued?
According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued.
Does Cogent Biosciences pay dividends?
Cogent Biosciences does not currently pay dividends.
What is Cogent Biosciences’s EPS estimate?
Cogent Biosciences’s EPS estimate is -0.51.
How many shares outstanding does Cogent Biosciences have?
Cogent Biosciences has 152,053,960 shares outstanding.
What happened to Cogent Biosciences’s price movement after its last earnings report?
Cogent Biosciences reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.516. Following the earnings report the stock price went down -4.908%.
Which hedge fund is a major shareholder of Cogent Biosciences?
Currently, no hedge funds are holding shares in COGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogent Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.00 (37.02% Upside)
$52.00 (37.02% Upside)
Blogger Sentiment
Bullish
COGT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 9.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $139.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
334.21%
12-Months-Change
Fundamentals
Return on Equity
-95.40%
Trailing 12-Months
Asset Growth
10.92%
Trailing 12-Months
Company Description
Cogent Biosciences
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
COGT Stock 12 Month Forecast
Average Price Target
$52.00
▲(37.02% Upside)
Technical Analysis
IDEAYA Biosciences
―
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
Currently, No data available
---